fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

MHRA (UK) approves Jeragyo (aprocitentan) to treat resistant hypertension – Idorsia

Written by | 23 Jan 2025 | Cardiology

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jeraygo (aprocitentan) to treat hypertension (high blood pressure) in adults whose blood pressure cannot be adequately controlled by at least three other medicines (also known as resistant hypertension).

The new marketing authorization was granted in 106 days on January 8 to Idorsia Pharmaceuticals Deutschland GmbH under the International Recognition Procedure (IRP) Route B. In July last year, the European Commission approved Idorsia’s Jeraygo for the same indication.

It was also approved under the trade name Tryvio in March last year.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.